Back to Newsroom
Back to Newsroom

Lawsuits Filed Against GDRX, TRIT and TCDA - Jakubowitz Law Pursues Shareholders Claims

Tuesday, 12 January 2021 11:30 AM

Jakubowitz Law

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / January 12, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

GoodRx Holdings, Inc (NASDAQ:GDRX)

CONTACT JAKUBOWITZ ABOUT GDRX:
https://claimyourloss.com/securities/goodrx-holdings-inc-loss-submission-form/?id=12103&from=1

Class Period: September 23, 2020 - November 16, 2020

Lead Plaintiff Deadline: February 16, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: at the time of the IPO, unbeknownst to investors, Amazon.com, Inc. was developing and would soon introduce its own online and mobile prescription medication ordering and fulfillment service that would directly compete with GoodRx. Defendants timed the IPO so that it was priced before Amazon announced its online pharmaceutical business to facilitate the IPO and create artificial demand for the common shares sold therein, as well to maximize the amount of money the Company and the selling stockholders could raise in the IPO. Given defendants' knowledge of Amazon's intention to enter the online pharmaceutical business, and their misleading statements about GoodRx's competitive position made contemporaneously with that knowledge, defendants' materially false and/or misleading statements alleged herein were made willfully and caused GoodRx common stock to trade at artificially inflated prices during the Class Period.

Triterras, Inc., f/k/a Netfin Acquisition Corp. (NASDAQ:TRIT)

CONTACT JAKUBOWITZ ABOUT TRIT:
https://claimyourloss.com/securities/triterras-inc-f-k-a-netfin-acquisition-corp-loss-submission-form/?id=12103&from=1

Class Period: August 20, 2020 - December 16, 2020

Lead Plaintiff Deadline: February 19, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the extent to which Company's revenue growth relied on Triterras' relationship with Rhodium to refer users to the Kratos platform; (2) that Rhodium faced significant financial liabilities that jeopardized its ability to continue as a going concern; (3) that, as a result, Rhodium was likely to refer fewer users to the Company's Kratos platform; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Tricida, Inc. (NASDAQ:TCDA)

CONTACT JAKUBOWITZ ABOUT TCDA:
https://claimyourloss.com/securities/tricida-inc-loss-submission-form/?id=12103&from=1

Class Period: September 4, 2019 - October 28, 2020

Lead Plaintiff Deadline: March 8, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Tricida's NDA for veverimer was materially deficient; (ii) accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law, Tuesday, January 12, 2021, Press release picture

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: